Medical Diagnostics Company STAT-­Diagnostica Secures 22.1 Million USD/17 Million Euros in Series B Financing

STAT-Diagnostica has announced the closing of a Series B financing round totaling 22.1 million USD/17 million Euros, the proceeds of which will be used to complete development of the company's Near Patient Testing diagnostic system and clinical validation of its first products. Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest; Boehringer Ingelheim Venture Fund; and, Caixa Capital Risc, the venture capital division of "la Caixa;" as well as existing investors Ysios Capital and Axis. 
 
Founded in 2010 and based in the Barcelona Science Park, STAT­-Diagnostica develops Near Patient Testing systems that simplify and reduce time to results for the diagnosis of certain medical conditions. The company's novel in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device. The first clinical applications will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.
 
"The Series B financing is a significant milestone that will support our preparation for a European market launch in 2015," said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. "Our ability to close the round is proof of the outstanding team behind the company, and demonstrates the potential of our technology in the fast growing decentralized diagnostics market." 
 
STAT-Diagnostica's platform not only offers multi-analyte and multi-sample capabilities, but it also reduces current diagnosis times (which can take up to several days) by providing results in less than 30 minutes. The system's rapid performance will enable improved clinical decision making by medical practitioners, delivering better patient management with direct and indirect savings to the healthcare system. 
  
Grant Thornton acted as financial advisor for the new investors and Cuatrecasas as legal advisor. Rousaud Costas Duran acted as legal advisor for the company